First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Dysregulation of Met receptor tyrosine kinase activity in invasive tumors

Alla Danilkovitch‐Miagkova, Berton Zbar · Journal of Clinical Investigation · 2002 · 244 citations · Full text

Medicine, Cancer Biology, Oncology +14

Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment

Puyu Shi, You-Take Oh, Guojing Zhang et al. · Cancer Letters · 2016 · 182 citations

Medicine, Molecular Biology, Oncology +14

The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target

Juliano D. Paccez, Gabriela J Vasques, Ricardo G. Correa et al. · Oncogene · 2012 · 135 citations · Full text

Medicine, Molecular Biology, Oncology +16

Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma

Kevin B. Kim, Jason Chesney, Douglas Robinson et al. · Clinical Cancer Research · 2011 · 122 citations · Full text

Medicine, Oncology, Pharmacology +15